50. Dermatomyositis Clinical trials / Disease details
Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05524311 (ClinicalTrials.gov) | November 10, 2022 | 5/7/2022 | Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) | Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis | Juvenile Dermatomyositis | Drug: Baricitinib;Biological: pharmacokinetics study;Biological: dosage of cytokines;Biological: transcriptomic analysis;Behavioral: Parent version of the Child Health Questionnaire (CHQ);Behavioral: Childhood Health Assessment Questionnaire;Biological: Pregnancy test | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 3 Years | 18 Years | All | 16 | Phase 2 | France |
| 2 | NCT04972760 (ClinicalTrials.gov) | August 31, 2022 | 14/6/2021 | Baricitinib in Patients With Relapsing or naïve Dermatomyositis | Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD) | Dermatomyositis | Drug: Baricitinib;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | 74 Years | All | 62 | Phase 3 | France |
| 3 | NCT05361109 (ClinicalTrials.gov) | May 1, 2022 | 3/4/2022 | Baricitinib for Cutaneous Dermatomyositis | An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Baricitinib in Subjects With Cutaneous Dermatomyositis | Dermatomyositis | Drug: Baricitinib | University of Washington | NULL | Not yet recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 4 | NCT01724580 (ClinicalTrials.gov) | October 2012 | 5/11/2012 | Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes | Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE);Juvenile Dermatomyositis (JDM);Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI);Aicardi-Goutières Syndrome (AGS) | Drug: Baricitinib | Eli Lilly and Company | NULL | No longer available | 6 Months | N/A | All | United States;United Kingdom | ||
| 5 | EUCTR2015-003424-31-GB (EUCTR) | 07/12/2015 | Treatment of autoinflammatory diseases | Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis - JAGA | CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Baricitinib Product Code: LY3009104 INN or Proposed INN: Baricitinib Other descriptive name: BARICITINIB INN or Proposed INN: Baricitinib Other descriptive name: BARICITINIB INN or Proposed INN: baricitinib Other descriptive name: BARICITINIB | Eli Lilly and Company | NULL | NA | Female: yes Male: yes | 60 | Phase 2 | France;United States;United Kingdom |